Canadian Medical Association Journal, Vol 146, Issue 4 473-481, Copyright © 1992 by Canadian Medical Association

JOURNAL ARTICLE

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

A. Laupacis, D. Feeny, A. S. Detsky and P. X. Tugwell
Department of Medicine, University of Ottawa, Ont.

Because economic evaluations of health care services are being published with increasing frequency it is important to (a) evaluate them rigorously and (b) compare the net benefit of the application of one technology with that of others. Four "levels of evidence" that rate economic evaluations on the basis of their methodologic rigour are proposed. They are based on the quality of the methods used to estimate clinical effectiveness, quality of life and costs. With the use of the magnitude of the incremental net benefit of a technology, therapies can also be classified into five "grades of recommendation." A grade A technology is both more effective and cheaper than the existing one, whereas a grade E technology is less or equally effective and more costly. Those of grades B through D are more effective and more costly. A grade B technology costs less than $20,000 per quality-adjusted life-year (QALY), a grade C one $20,000 to $100,000/QALY and a grade D one more than $100,000/QALY. Many issues other than cost effectiveness, such as ethical and political considerations, affect the implementation of a new technology. However, it is hoped that these guidelines will provide a framework with which to interpret economic evaluations and to identify additional information that will be useful in making sound decisions on the adoption and utilization of health care services.

This article has been cited by other articles:

				J. A. Rihn, S. Berven, T. Allen, F. M. Phillips, B. L. Currier, S. D. Glassman, D. B. Nash, C. Mick, A. Crockard, and T. J. Albert Defining Value in Spine Care American Journal of Medical Quality, November 1, 2009; 24(6_suppl): 4S - 14S. [Abstract] [PDF]

				A. R. Patrick, J. Avorn, and N. K. Choudhry Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation Circ Cardiovasc Qual Outcomes, September 1, 2009; 2(5): 429 - 436. [Abstract] [Full Text] [PDF]

				S. Subramanian, G. Bobashev, and R. J. Morris Modeling the Cost-Effectiveness of Colorectal Cancer Screening: Policy Guidance Based on Patient Preferences and Compliance Cancer Epidemiol. Biomarkers Prev., July 1, 2009; 18(7): 1971 - 1978. [Abstract] [Full Text] [PDF]

				G. Chodick, O. Waisbourd-Zinman, V. Shalev, E. Kokia, M. Rabinovich, and S. Ashkenazi Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel Eur J Public Health, June 1, 2009; 19(3): 254 - 259. [Abstract] [Full Text] [PDF]

				B. Reider Show Me the Money! Am. J. Sports Med., June 1, 2009; 37(6): 1075 - 1076. [Full Text] [PDF]

				N. H. Shusterman and H. Erder Adjusting for Inflation and Higher Surgery Costs in a Cost-Effectiveness Study of Spinal Surgery Ann Intern Med, May 5, 2009; 150(9): 652 - 652. [Full Text] [PDF]

				A. N.A. Tosteson, J. N. Weinstein, and J. S. Skinner Adjusting for Inflation and Higher Surgery Costs in a Cost-Effectiveness Study of Spinal Surgery Ann Intern Med, May 5, 2009; 150(9): 652 - 653. [Full Text] [PDF]

				C. G. Cameron MSc and H. A. Bennett BPharm PhD Cost-effectiveness of insulin analogues for diabetes mellitus Can. Med. Assoc. J., February 17, 2009; 180(4): 400 - 407. [Abstract] [Full Text] [PDF]

				A. L. Chan, H. W. Leung, C.-L. Lu, and S. J. Lin Cost-Effectiveness of Trastuzumab as Adjuvant Therapy for Early Breast Cancer: A Systematic Review Ann. Pharmacother., February 1, 2009; 43(2): 296 - 303. [Abstract] [Full Text] [PDF]

				A. N.A. Tosteson, J. D. Lurie, T. D. Tosteson, J. S. Skinner, H. Herkowitz, T. Albert, S. D. Boden, K. Bridwell, M. Longley, G. B. Andersson, et al. Surgical Treatment of Spinal Stenosis with and without Degenerative Spondylolisthesis: Cost-Effectiveness after 2 Years Ann Intern Med, December 16, 2008; 149(12): 845 - 853. [Abstract] [Full Text] [PDF]

				A. M. Bayoumi MD MSc and G. S. Zaric PhD The cost-effectiveness of Vancouver's supervised injection facility Can. Med. Assoc. J., November 18, 2008; 179(11): 1143 - 1151. [Abstract] [Full Text] [PDF]

				C. S. Poon A Brief Commentary on Cost-Effectiveness Analysis in Radiologic Research Am. J. Roentgenol., November 1, 2008; 191(5): 1320 - 1322. [Abstract] [Full Text] [PDF]

				E. Remak, C. Charbonneau, S. Negrier, S. T. Kim, and R. J. Motzer Economic Evaluation of Sunitinib Malate for the First-Line Treatment of Metastatic Renal Cell Carcinoma J. Clin. Oncol., August 20, 2008; 26(24): 3995 - 4000. [Abstract] [Full Text] [PDF]

				A. D. I. van Asselt, C. D. Dirksen, A. Arntz, J. H. Giesen-Bloo, R. van Dyck, P. Spinhoven, W. van Tilburg, I. P. Kremers, M. Nadort, and J. L. Severens Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v. transference-focused psychotherapy The British Journal of Psychiatry, June 1, 2008; 192(6): 450 - 457. [Abstract] [Full Text] [PDF]

				J. M. Llovet, A. M. Di Bisceglie, J. Bruix, B. S. Kramer, R. Lencioni, A. X. Zhu, M. Sherman, M. Schwartz, M. Lotze, J. Talwalkar, et al. Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma J Natl Cancer Inst, May 21, 2008; 100(10): 698 - 711. [Abstract] [Full Text] [PDF]

				K. M. Jackson, K. E. Scott, J. Graff Zivin, D. A. Bateman, J. T. Flynn, J. D. Keenan, and M. F. Chiang Cost-Utility Analysis of Telemedicine and Ophthalmoscopy for Retinopathy of Prematurity Management Arch Ophthalmol, April 1, 2008; 126(4): 493 - 499. [Abstract] [Full Text] [PDF]

				A. N.A. Tosteson, N. K. Stout, D. G. Fryback, S. Acharyya, B. A. Herman, L. G. Hannah, E. D. Pisano, and for the DMIST Investigators Cost-Effectiveness of Digital Mammography Breast Cancer Screening Ann Intern Med, January 1, 2008; 148(1): 1 - 10. [Abstract] [Full Text] [PDF]

				E. J. Novak, M. D. Silverstein, and K. J. Bozic The Cost-Effectiveness of Computer-Assisted Navigation in Total Knee Arthroplasty J. Bone Joint Surg. Am., November 1, 2007; 89(11): 2389 - 2397. [Abstract] [Full Text] [PDF]

				B. Manns, S. Klarenbach, H. Lee, B. Culleton, F. Shrive, and M. Tonelli Economic evaluation of sevelamer in patients with end-stage renal disease Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2867 - 2878. [Abstract] [Full Text] [PDF]

				F. R. Ernst, H. Levy, and R. L. Qualy Simplified Pharmacoeconomics of Critical Care and Severe Sepsis J Intensive Care Med, September 1, 2007; 22(5): 283 - 293. [Abstract] [PDF]

				A. J. H. A. Ament, M. W. A. Hubben, P. E. Verweij, R. de Groot, A. Warris, J. P. Donnelly, J. v. t Wout, and J. L. Severens Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach J. Antimicrob. Chemother., August 1, 2007; 60(2): 385 - 393. [Abstract] [Full Text] [PDF]

				A. S. Detsky and A. Laupacis Relevance of Cost-effectiveness Analysis to Clinicians and Policy Makers JAMA, July 11, 2007; 298(2): 221 - 224. [Full Text] [PDF]

				R. Ng, B. Hasan, N. Mittmann, M. Florescu, F. A. Shepherd, K. Ding, C. A. Butts, Y. Cormier, G. Darling, G. D. Goss, et al. Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non-Small-Cell Lung Cancer--A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol., June 1, 2007; 25(16): 2256 - 2261. [Abstract] [Full Text] [PDF]

				Y. Wu, G. L. Grunkemeier, and A. Starr The value of aortic valve replacement in elderly patients: An economic analysis J. Thorac. Cardiovasc. Surg., March 1, 2007; 133(3): 603 - 607. [Abstract] [Full Text] [PDF]

				Y. Wu, R. Jin, G. Gao, G. L. Grunkemeier, and A. Starr Cost-effectiveness of aortic valve replacement in the elderly: An introductory study J. Thorac. Cardiovasc. Surg., March 1, 2007; 133(3): 608 - 613. [Abstract] [Full Text] [PDF]

				N. L. Liberato, M. Marchetti, and G. Barosi Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer J. Clin. Oncol., February 20, 2007; 25(6): 625 - 633. [Abstract] [Full Text] [PDF]

				M. Dubik Screening for Long QT Syndrome AAP Grand Rounds, November 1, 2006; 16(5): 49 - 50. [Full Text] [PDF]

				S. Quaglini, C. Rognoni, C. Spazzolini, S. G. Priori, S. Mannarino, and P. J. Schwartz Cost-effectiveness of neonatal ECG screening for the long QT syndrome Eur. Heart J., August 1, 2006; 27(15): 1824 - 1832. [Abstract] [Full Text] [PDF]

				D. Feeny As Good As It Gets but Good Enough for Which Applications? Med Decis Making, July 1, 2006; 26(4): 307 - 309. [PDF]

				D. A. Regier, R. Sunderji, L. D. Lynd, K. Gin, and C. A. Marra Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. Can. Med. Assoc. J., June 20, 2006; 174(13): 1847 - 1852. [Abstract] [Full Text] [PDF]

				P. G. O'Malley Atherosclerosis imaging of asymptomatic individuals: is the sales cart before the evidence horse? Arch Intern Med, May 22, 2006; 166(10): 1065 - 1068. [Full Text] [PDF]

				R. Shamir, O. Hernell, and M. Leshno Cost-Effectiveness Analysis of Screening for Celiac Disease in the Adult Population Med Decis Making, May 1, 2006; 26(3): 282 - 293. [Abstract] [PDF]

				D. M. G. Halpin Health Economics of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2006; 3(3): 227 - 233. [Abstract] [Full Text] [PDF]

				C. A. Dooms, Y. N. Lievens, and J. F. Vansteenkiste Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer Eur. Respir. J., May 1, 2006; 27(5): 895 - 901. [Abstract] [Full Text] [PDF]

				C. M Bell, D. R Urbach, J. G Ray, A. Bayoumi, A. B Rosen, D. Greenberg, and P. J Neumann Bias in published cost effectiveness studies: systematic review BMJ, March 25, 2006; 332(7543): 699 - 703. [Abstract] [Full Text] [PDF]

				O. H Franco, E. W Steyerberg, and C. de Laet The polypill: at what price would it become cost effective? J Epidemiol Community Health, March 1, 2006; 60(3): 213 - 217. [Abstract] [Full Text] [PDF]

				L. R. Mobley, T. J. Hoerger, J. S. Wittenborn, D. A. Galuska, and J. K. Rao Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate Med Decis Making, March 1, 2006; 26(2): 194 - 206. [Abstract] [PDF]

				J. D. Miller, R. A. Malthaner, C. H. Goldsmith, R. Goeree, D. Higgins, P. G. Cox, L. Tan, J. D. Road, and Canadian Lung Volume Reduction Surgery Study A Randomized Clinical Trial of Lung Volume Reduction Surgery Versus Best Medical Care for Patients With Advanced Emphysema: A Two-Year Study From Canada Ann. Thorac. Surg., January 1, 2006; 81(1): 314 - 321. [Abstract] [Full Text] [PDF]

				G. Guyatt, M. Baumann, S. Pauker, J. Halperin, J. Maurer, D. K. Owens, A. N.A. Tosteson, B. Carlin, D. Gutterman, M. Prins, et al. Addressing Resource Allocation Issues in Recommendations From Clinical Practice Guideline Panels: Suggestions From an American College of Chest Physicians Task Force Chest, January 1, 2006; 129(1): 182 - 187. [Abstract] [Full Text] [PDF]

				O. H Franco, A. Peeters, C. W N Looman, and L. Bonneux Cost effectiveness of statins in coronary heart disease J Epidemiol Community Health, November 1, 2005; 59(11): 927 - 933. [Abstract] [Full Text] [PDF]

				M. M. Byrne, K. O'Malley, and M. E. Suarez-Almazor Willingness to Pay per Quality-Adjusted Life Year in a Study of Knee Osteoarthritis Med Decis Making, November 1, 2005; 25(6): 655 - 666. [Abstract] [PDF]

				J. T. King Jr., J. Tsevat, J. R. Lave, and M. S. Roberts Willingness to Pay for a Quality-Adjusted Life Year: Implications for Societal Health Care Resource Allocation Med Decis Making, November 1, 2005; 25(6): 667 - 677. [Abstract] [PDF]

				F. L. Lynch, M. Hornbrook, G. N. Clarke, N. Perrin, M. R. Polen, E. O'Connor, and J. Dickerson Cost-effectiveness of an Intervention to Prevent Depression in At-Risk Teens Arch Gen Psychiatry, November 1, 2005; 62(11): 1241 - 1248. [Abstract] [Full Text] [PDF]

				S. J. Heitman, B. J. Manns, R. J. Hilsden, A. Fong, S. Dean, and J. Romagnuolo Cost-effectiveness of computerized tomographic colonography versus colonoscopy for colorectal cancer screening Can. Med. Assoc. J., October 11, 2005; 173(8): 877 - 881. [Abstract] [Full Text] [PDF]

				M. Cecchi, E. Caccese, A. Messori, J. P. Vandenbroucke, J. R. Kroep, P. G. Richardson, A. L. Boral, and K. C. Anderson Bortezomib in Multiple Myeloma N. Engl. J. Med., September 22, 2005; 353(12): 1297 - 1298. [Full Text] [PDF]

				M. M. Engelgau Trying To Predict the Future for People with Diabetes: A Tough but Important Task Ann Intern Med, August 16, 2005; 143(4): 301 - 302. [Full Text] [PDF]

				I. T. Lagomasino, M. Dwight-Johnson, and G. M. Simpson Psychopharmacology: The Need for Effectiveness Trials to Inform Evidence-Based Psychiatric Practice Psychiatr Serv, June 1, 2005; 56(6): 649 - 651. [Full Text] [PDF]

				C. A. Brauer, A. B. Rosen, N. V. Olchanski, and P. J. Neumann Cost-Utility Analyses in Orthopaedic Surgery J. Bone Joint Surg. Am., June 1, 2005; 87(6): 1253 - 1259. [Abstract] [Full Text] [PDF]

				D N Fisman Health related quality of life in genital herpes: a pilot comparison of measures Sex Transm Inf, June 1, 2005; 81(3): 267 - 270. [Abstract] [Full Text] [PDF]

				W. H. Herman, T. J. Hoerger, M. Brandle, K. Hicks, S. Sorensen, P. Zhang, R. F. Hamman, R. T. Ackermann, M. M. Engelgau, R. E. Ratner, et al. The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance Ann Intern Med, March 1, 2005; 142(5): 323 - 332. [Abstract] [Full Text] [PDF]

				K. Rost, J. M. Pyne, L. M. Dickinson, and A. T. LoSasso Cost-Effectiveness of Enhancing Primary Care Depression Management on an Ongoing Basis Ann. Fam. Med, January 1, 2005; 3(1): 7 - 14. [Abstract] [Full Text] [PDF]

				L. M. Dickinson, K. Rost, P. A. Nutting, C. E. Elliott, R. D. Keeley, and H. Pincus RCT of a Care Manager Intervention for Major Depression in Primary Care: 2-Year Costs for Patients With Physical vs Psychological Complaints Ann. Fam. Med, January 1, 2005; 3(1): 15 - 22. [Abstract] [Full Text] [PDF]

				J. Avorn and W. C. Winkelmayer Comparing the Costs, Risks, and Benefits of Competing Strategies for the Primary Prevention of Venous Thromboembolism Circulation, December 14, 2004; 110(24_suppl_1): IV-25 - IV-32. [Abstract] [Full Text] [PDF]

				D. A. Marshall, A. R. Levy, H. Vidaillet, E. Fenwick, A. Slee, G. Blackhouse, H. L. Greene, D. G. Wyse, G. Nichol, B. J. O'Brien, et al. Cost-Effectiveness of Rhythm versus Rate Control in Atrial Fibrillation Ann Intern Med, November 2, 2004; 141(9): 653 - 661. [Abstract] [Full Text] [PDF]

				D. J. Pennell, U. P. Sechtem, C. B. Higgins, W. J. Manning, G. M. Pohost, F. E. Rademakers, A. C. van Rossum, L. J. Shaw, and E. K. Yucel Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report Eur. Heart J., November 1, 2004; 25(21): 1940 - 1965. [Full Text] [PDF]

				The two-step to two-tier Can. Med. Assoc. J., September 14, 2004; 171(6): 541 - 541. [Full Text] [PDF]

				La medecine a deux vitesses en deux temps Can. Med. Assoc. J., September 14, 2004; 171(6): 543 - 543. [Full Text] [PDF]

				C Hopley, G Salkeld, and P Mitchell Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration Br J Ophthalmol, August 1, 2004; 88(8): 982 - 987. [Abstract] [Full Text] [PDF]

				M. D Rawlins and A. J Culyer National Institute for Clinical Excellence and its value judgments BMJ, July 24, 2004; 329(7459): 224 - 227. [Full Text] [PDF]

				D. M. Kent, A. M. Fendrick, and K. M. Langa New and Dis-Improved: On the Evaluation and Use of Less Effective, Less Expensive Medical Interventions Med Decis Making, June 1, 2004; 24(3): 281 - 286. [Abstract] [PDF]

				K. J. Bozic, R. G. Pierce, and J. H. Herndon Health Care Technology Assessment. Basic Principles and Clinical Applications J. Bone Joint Surg. Am., June 1, 2004; 86(6): 1305 - 1314. [Abstract] [Full Text] [PDF]

				S Petrou and L Edwards Cost effectiveness analysis of neonatal extracorporeal membrane oxygenation based on four year results from the UK Collaborative ECMO Trial Arch. Dis. Child. Fetal Neonatal Ed., May 1, 2004; 89(3): F263 - F268. [Abstract] [Full Text] [PDF]

				M. C. Riddle Diabetes: Too Big and Too Bad to Ignore Any Longer Clin. Diabetes, April 1, 2004; 22(2): 90 - 91. [Full Text] [PDF]

				C Hopley, G Salkeld, J J Wang, and P Mitchell Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants Br J Ophthalmol, April 1, 2004; 88(4): 450 - 454. [Abstract] [Full Text] [PDF]

				J. P. Abenstein, K. H. Long, B. P. McGlinch, and N. M. Dietz Is Physician Anesthesia Cost-Effective? Anesth. Analg., March 1, 2004; 98(3): 750 - 757. [Abstract] [Full Text] [PDF]

				E. Warren, A. Brennan, and R. Akehurst Cost-Effectiveness of Sibutramine in the Treatment of Obesity Med Decis Making, January 1, 2004; 24(1): 9 - 19. [Abstract] [PDF]

				C. B. Baker, M. T. Johnsrud, M. L. Crismon, R. A. Rosenheck, and S. W. Woods Quantitative analysis of sponsorship bias in economic studies of antidepressants The British Journal of Psychiatry, December 1, 2003; 183(6): 498 - 506. [Abstract] [Full Text] [PDF]

				L. N. Venditti, C. P. Venditti, G. T. Berry, P. B. Kaplan, E. M. Kaye, H. Glick, and C. A. Stanley Newborn Screening by Tandem Mass Spectrometry for Medium-Chain Acyl-CoA Dehydrogenase Deficiency: A Cost-Effectiveness Analysis Pediatrics, November 1, 2003; 112(5): 1005 - 1015. [Abstract] [Full Text] [PDF]

				Diabetes Prevention Program Research Group Within-Trial Cost-Effectiveness of Lifestyle Intervention or Metformin for the Primary Prevention of Type 2 Diabetes Diabetes Care, September 1, 2003; 26(9): 2518 - 2523. [Abstract] [Full Text] [PDF]

				National Emphysema Treatment Trial Research Group Cost Effectiveness of Lung-Volume-Reduction Surgery for Patients with Severe Emphysema N. Engl. J. Med., May 22, 2003; 348(21): 2092 - 2102. [Abstract] [Full Text] [PDF]

				L. D. Wurtz, J. R. Feinberg, W. N. Capello, R. Meldrum, and P. J. Kay Elective Primary Total Hip Arthroplasty in Octogenarians J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2003; 58(5): M468 - 471. [Abstract] [Full Text] [PDF]

				K. Wilson and P. C. Hebert The challenge of an increasingly expensive blood system Can. Med. Assoc. J., April 29, 2003; 168(9): 1149 - 1150. [Full Text] [PDF]

				A. Gafni and S. Birch Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures? Can. Med. Assoc. J., April 1, 2003; 168(7): 849 - 851. [Full Text] [PDF]

				J. Mar, J.R. Rueda, J. Duran-Cantolla, C. Schechter, and J. Chilcott The cost-effectiveness of nCPAP treatment in patients with moderate-to-severe obstructive sleep apnoea Eur. Respir. J., March 1, 2003; 21(3): 515 - 522. [Abstract] [Full Text] [PDF]

				M. A. Joore, H. van der Stel, H. J. M. Peters, G. M. Boas, and L. J. C. Anteunis The Cost-effectiveness of Hearing-Aid Fitting in the Netherlands Arch Otolaryngol Head Neck Surg, March 1, 2003; 129(3): 297 - 304. [Abstract] [Full Text] [PDF]

				D. Maberley, H. Walker, A. Koushik, and A. Cruess Screening for diabetic retinopathy in James Bay, Ontario: a cost-effectiveness analysis Can. Med. Assoc. J., January 21, 2003; 168(2): 160 - 164. [Abstract] [Full Text] [PDF]

				K. J. Bozic, A. G. Rosenberg, R. S. Huckman, and J. H. Herndon Economic Evaluationin Orthopaedics J. Bone Joint Surg. Am., January 17, 2003; 85(1): 129 - 142. [Full Text] [PDF]

				D. R. Lairson, C. E. Begley, T. F. Reynolds, and K. R. Wilhelmus Prevention of Herpes Simplex Virus Eye Disease: A Cost-effectiveness Analysis Arch Ophthalmol, January 1, 2003; 121(1): 108 - 112. [Abstract] [Full Text] [PDF]

				M. A. Kemler and C. A. Furnee Economic evaluation of spinal cord stimulation for chronic reflex sympathetic dystrophy Neurology, October 22, 2002; 59(8): 1203 - 1209. [Abstract] [Full Text] [PDF]

				N. Frohlich and N. P. Roos Searching for El Dorado: the impossibility of finding the right rate Can. Med. Assoc. J., October 15, 2002; 167(8): 880 - 881. [Full Text] [PDF]

				S. Saglam, B. Yetis, O. Ozyilkan, Z. Akcali, N. B. Leighl, F. A. Shepherd, and P. J. Goodwin Cost-Effectiveness of Chemotherapy in Non-Small-Cell Lung Cancer J. Clin. Oncol., September 1, 2002; 20(17): 3750 - 3752. [Full Text] [PDF]

				D. B. Mark and M. A. Hlatky Medical Economics and the Assessment of Value in Cardiovascular Medicine: Part I Circulation, July 23, 2002; 106(4): 516 - 520. [Full Text] [PDF]

				S Goodacre and C McCabe An introduction to economic evaluation Emerg. Med. J., May 1, 2002; 19(3): 198 - 201. [Abstract] [Full Text] [PDF]

				N. B. Leighl, F. A. Shepherd, R. Kwong, R. L. Burkes, R. Feld, and P. J. Goodwin Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., March 1, 2002; 20(5): 1344 - 1352. [Abstract] [Full Text] [PDF]

				M. M. Benade and C. P. Warlow Costs and Benefits of Carotid Endarterectomy and Associated Preoperative Arterial Imaging: A Systematic Review of Health Economic Literature Stroke, February 1, 2002; 33(2): 629 - 638. [Abstract] [Full Text] [PDF]

				R.E. Brown, R.A. Henderson, D. Koster, J. Hutton, and M.L. Simoons Cost effectiveness of eptifibatide in acute coronary syndromes. An economic analysis of Western European patients enrolled in the PURSUIT trial Eur. Heart J., January 1, 2002; 23(1): 50 - 58. [Abstract] [Full Text] [PDF]

				A. Laupacis Inclusion of drugs in provincial drug benefit programs: Who is making these decisions, and are they the right ones? Can. Med. Assoc. J., January 1, 2002; 166(1): 44 - 47. [Full Text] [PDF]

				J M Llovet, X Mas, J J Aponte, J Fuster, M Navasa, E Christensen, J Rodes, and J Bruix Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation Gut, January 1, 2002; 50(1): 123 - 128. [Abstract] [Full Text] [PDF]

				R. Sheldon, B. J. O'Brien, G. Blackhouse, R. Goeree, B. Mitchell, G. Klein, R. S. Roberts, M. Gent, and S. J. Connolly Effect of Clinical Risk Stratification on Cost-Effectiveness of the Implantable Cardioverter-Defibrillator: The Canadian Implantable Defibrillator Study Circulation, October 2, 2001; 104(14): 1622 - 1626. [Abstract] [Full Text] [PDF]

				J. T.R. Clarke, D. Amato, and R. B. Deber Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario Can. Med. Assoc. J., September 1, 2001; 165(5): 595 - 596. [Full Text] [PDF]

				L.J. Shaw, D.S. Berman, and D.D. Miller Cost-effectiveness of myocardial perfusion imaging in the evaluation of patients with known or suspected coronary artery disease Eur. Heart J. Suppl., September 1, 2001; 3(suppl_F): F15 - F18. [Abstract] [PDF]

				K. J. Tomaszewski and R. G. Holloway Deep brain stimulation in the treatment of Parkinson's disease: A cost-effectiveness analysis Neurology, August 28, 2001; 57(4): 663 - 671. [Abstract] [Full Text] [PDF]

				M. E. Singer and K. E. Applegate Cost-Effectiveness Analysis in Radiology Radiology, June 1, 2001; 219(3): 611 - 620. [Abstract] [Full Text] [PDF]

				P. M. McMahon, J. L. Bosch, S. Gleason, E. F. Halpern, J. S. Lester, and G. S. Gazelle Cost-Effectiveness of Colorectal Cancer Screening Radiology, April 1, 2001; 219(1): 44 - 50. [Abstract] [Full Text]

				A. P. Hallstrom, J. H. McAnulty, B. L. Wilkoff, D. Follmann, M. H. Raitt, M. D. Carlson, A. M. Gillis, H.-T. Shih, J. L. Powell, H. Duff, et al. Patients at lower risk of arrhythmia recurrence: a subgroup in whom implantable defibrillators may not offer benefit J. Am. Coll. Cardiol., March 15, 2001; 37(4): 1093 - 1099. [Abstract] [Full Text] [PDF]

				B. J. O'Brien, S. J. Connolly, R. Goeree, G. Blackhouse, A. Willan, R. Yee, R. S. Roberts, and M. Gent Cost-Effectiveness of the Implantable Cardioverter-Defibrillator : Results From the Canadian Implantable Defibrillator Study (CIDS) Circulation, March 13, 2001; 103(10): 1416 - 1421. [Abstract] [Full Text] [PDF]

HOME	CURRENT ISSUE	PAST ISSUES	COLLECTIONS	HELP	SEARCH
Copyright 1995-1992, Canadian Medical Association. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p) All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.